Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

ATI starts investigational neurostimulation system European study

Autonomic Technologies (ATI) has started an European study of its investigational neurostimulation system.

The multi-center, randomized Pathway M-1 study, which will enroll 30 patients, is designed to assess the safety and efficacy of neurostimulation system for the treatment of migraine.

The company’s neurostimulation system is also currently being assesed in the Pathway CH-1 study for the treatment of cluster headache.

The interim results of the study demonstrated pain relief in 59% of headaches treated.

Autonomic Technologies president and CEO Ben Pless said building on their therapy’s promising results in cluster headache, ATI and their investigator team are excited to begin clinical work with migraine patients.

"We hope that our work may one day offer relief to tens of thousands of severe headache sufferers,"
Pless added.